疏肝健脾方治疗糖尿病前期46例  

Shugan Jianpi Decoction Treatment Early-stage Diabetes with 46 Cases

作　　者：祝继英[1] 秦佰焰 王明贤[3] 封加福[3] 江玉[4] 

机构地区：[1]雅安职业技术学院,四川雅安625500 [2]峨眉山市中医院,四川乐山614200 [3]乐山职业技术学院,四川乐山614000 [4]泸州医学院附属中医院,四川泸州646000

出　　处：《中国实验方剂学杂志》2014年第14期188-192,共5页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：四川省教育厅项目(川教函[2011]538号11ZB130)

摘　　要：目的:观察疏肝健脾方对糖尿病前期患者糖代谢、脂代谢的调节作用及对炎性因子的影响。方法:91例糖尿病前期患者随机按就诊顺序分为对照组45例和观察组46例。对照组服用吡格列酮二甲双胍片,1片/次,2次/d。观察组服用疏肝健脾方,1剂/d。两组疗程均为12周。测量治疗后体重、腰围;检测治疗前后血脂水平,包括甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)及低密度脂蛋白胆固醇(LDL-C);检测治疗前后空腹血糖(FBG)、空腹胰岛素(FINS)、餐后2 h血糖(2 hPG)及糖化血红蛋白(HbAlc),计算体重指数(BMI)、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞分泌功能指数(HOMA-IS)和胰岛素敏感指数(ISI);检测治疗前后血清脂联素(APN)、白细胞介素(IL-6)和超敏C-反应蛋白(hs-CRP)水平。结果:治疗后两组腰围和BMI均较治疗前下降,组间比较差异无统计学意义,治疗后两组体重均呈下降趋势;观察组FBG,2hPG,HbA1c及FINS水平低于对照组(P<0.05或P<0.01);观察组HOMA-IR低于对照组(P<0.01),HOMA-IS和ISI高于对照组(P<0.01);观察组TC,TG,LDL-C和HDL-C单项指标转为正常例数多于对照组(P<0.01);观察组血清APN高于对照组(P<0.01),观察组IL-6和hs-CRP水平低于对照组(P<0.01)。结论:疏肝健脾方能调节糖尿病前期患者的糖代谢、脂代谢,延缓或逆转其进展为糖尿病的速度,其作用机制可能与调节APN,IL-6及hs-CRP等因子有关。Objective： Observe regulating effect of Shugan Jianpi decoction to patients＇ glucose metabolism and lipid metabolism in treating early-stage diabetes and influence to inflammatory factor. Method： Ninety-one patients with early-stage diabetes were randomly divided into control group （45 cases） and observation group （46 cases） according to registration order. Patients in control group received pioglitazone hydrochloride and metformin hydrochloride tablets, 1 tablet/time, 2 times/day, taken orally. Patients in observation group received Shugan Jianpi decoction, 1 dose/day. Course of treatment in two groups were both 12 weeks. After treatment, patients＇ weight and waist were measured, and levels of blood lipid was detected which including triglyceride （TG）, total cholesterol （ TC）, high-density lipoprotein （HDL-C） and low density lipoprotein （LDL-C）. Before and after treatment, fasting blood-glucose （FBG）, fasting insulin （FINS）, 2 hours postprandial blood glucose （2 hPG）and glycosylated hemoglobin （HbAlc）were detected, body mass index （BMI）, homeostasismodel assessment-insulin resistance index （HOMA-IR） of insulin, homeostasis model assessment-insulin secretion of pancreatic fl-cell and insulin sensitivity index （ISI） were detected, and levels of adiponectin （APN）, interleukin-6 （IL-6） and high-sensitivity c-reactive protein （hs-CRP） were also detected. Result： After treatment, compared with the time before treatment, waist and BMI in two groups decreased, which means no statistical significance from the differences between two groups, and there was a decreasing tendency of patients＇ weight. Levels of FBG, 2 hPG, HbAlc and FINS in observation group were lower than those in control group （P〈0.05 or P 〈 0.01）. HOMA-IR in observation group was lower than in control group （P 〈 0.01 ） and HOMA-IS and ISI were higher than those in control group （P 〈 0.01 ）. Cases of turning normal of TC, TG, LDL-C and HDL-C in observation group

关 键 词：糖尿病前期 疏肝健脾 糖代谢 脂代谢 脂联素 白细胞介素 超敏C-反应蛋白 

分 类 号：R287[医药卫生—中药学]